Drug Discovery to Development Innovation Forum Speakers
High-throughput technologies generate an ever increasing amount of biological and medical data. At the Quantitative Biology Center we develop methods for the management, processing and analysis for these large datasets.
Davide Gianni currently leads the Functional Genomics team in Discovery Sciences (AZ) in Cambridge UK. The main focus of the team is to identify novel target hypothesis for a range of therapy areas of interest for Astrazeneca.
Kenneth holds a Ph.D. in Synthetic Organic/Organometallic Chemistry from Massachusetts Institute of Technology and has pursued his Postdoctoral study in Natural product synthesis from the University of Texas.
Alastair has been closely involved with the discovery of UCB/Celltech’s therapeutic antibodies for thirty-five years, with Mylotarg®, Besponsa® and Cimzia® FDA-approved, and romosozumab, bimekizumab, dapirolizumab pegol and rozanoloxizumab in clinical trials.
Marina is Principal Research Scientist at the next generation biologics company Elasmogen. She is a member of a team of scientists developing novel single chain domains (soloMERs) from initial lead isolation through to clinical candidate identification.
Markus is a data scientist with a background functional genetic screening, engineering and bioinformatics and is leading the screening group and bioinformatics team at PhoreMost as their Chief Technology Officer.
In his role as Senior Vice President, Drug Discovery and amp; Platform Sciences, Vivek Vishnudas, Ph.D., oversees the development of experimental therapeutics from conception and drug discovery to first-in-human studies.
Vice President & Head, Genome Sciences & Technologies, Worldwide R&D
Morten Sogaard, VP Target Sciences at Pfizer oversees genetics, functional genomics, computational biology and target validation group as well as “Innovative target exploration networks” to generate first in class targets from emerging science.